

**INTEGRATIVE HOMEOPATHIC SUPPORTIVE CARE IN MYELOYDYSPLASTIC
SYNDROMES AND BONE MARROW FAILURE: A NARRATIVE REVIEW OF
CLINICAL EVIDENCE, BIOLOGICAL RATIONALE, AND FUTURE RESEARCH
DIRECTIONS****Professor Dr. A. K. Dwivedi***

Professor & Head, Department of Physiology & Biochemistry S.K.R.P. Gujarati Homoeopathic Medical College & Research Centre, Indore, Madhya Pradesh, India.

Director, Advanced Homeo Health Centre & Homoeopathic Medical Research Centre, Indore.

Member, Ethical Committee, Central Council for Research in Homoeopathy (CCRH), Ministry of AYUSH, Government of India.

Member, Scientific Advisory Committee (SAC), North Eastern Institute of Ayurveda & Homoeopathy (NEIAH), Shillong.

Member, Executive Council, Devi Ahilya Vishwavidyalaya (DAVV), Indore.

***Corresponding Author: Professor. Dr. A. K. Dwivedi**

Professor & Head, Department of Physiology & Biochemistry S.K.R.P. Gujarati Homoeopathic Medical College & Research Centre, Indore, Madhya Pradesh, India. DOI: <https://doi.org/10.5281/zenodo.21786153>



How to cite this Article: Professor. Dr. A. K. Dwivedi* (2026). Integrative Homeopathic Supportive Care In Myelodysplastic Syndromes And Bone Marrow Failure: A Narrative Review Of Clinical Evidence, Biological Rationale, And Future Research Directions. European Journal of Pharmaceutical and Medical Research, 13(8), 465–469.
This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 05/07/2026

Article Revised on 25/07/2026

Article Published on 01/08/2026

ABSTRACT


Background: Myelodysplastic Syndromes (MDS) are heterogeneous clonal disorders of hematopoietic stem cells characterized by ineffective haematopoiesis, peripheral cytopenias, transfusion dependency, and an increased risk of progression to acute myeloid leukaemia. Current conventional management focuses on supportive transfusions, erythropoiesis-stimulating agents, hypomethylating agents, immunosuppressive therapy, and hematopoietic stem cell transplantation. Despite these advances, many patients continue to experience persistent cytopenias, fatigue, recurrent infections, and reduced quality of life. **Objective:** To review the current literature regarding homeopathy as an integrative supportive therapy in MDS and bone marrow failure disorders and discuss potential mechanisms, clinical observations, and future research priorities. **Methods:** A narrative review of published literature, case reports, observational studies, and experimental research involving homeopathy in MDS, aplastic anaemia, and related bone marrow failure syndromes was undertaken. **Results:** Published reports suggest that individualized homeopathic treatment, particularly utilizing LM (50 millesimal) potencies alongside nutritional optimization and conventional haematology care, may improve fatigue, constitutional symptoms, haemoglobin levels, quality of life, and reduce transfusion requirements in selected patients. Experimental studies indicate possible immunomodulatory and hematopoietic effects of certain homeopathic preparations, although definitive mechanisms remain unclear. **Conclusion:** Current evidence remains limited to case reports, observational studies, and laboratory investigations. Homeopathy should presently be considered only as a complementary supportive modality within multidisciplinary haematological care. Well-designed randomized controlled trials are required before definitive clinical recommendations can be made.

KEYWORDS: Myelodysplastic Syndrome, Bone Marrow Failure, Homeopathy, Integrative Medicine, Cytopenia, Lm Potency, Quality Of Life, Haematopoiesis.

INTRODUCTION

Myelodysplastic Syndromes (MDS) comprise a diverse group of clonal hematopoietic disorders characterized by ineffective bone marrow function resulting in anaemia,

leukopenia, thrombocytopenia, or pancytopenia. The disease predominantly affects older adults and exhibits highly variable clinical behaviour.




Patients commonly present with

- Chronic anaemia
- Fatigue
- Dyspnoea
- Bleeding manifestations
- Recurrent infections
- Transfusion dependency
- Progressive marrow failure

Although contemporary haematology has significantly improved survival through disease-modifying therapies, many patients continue to suffer from persistent symptoms that adversely affect quality of life.

Complementary and integrative medicine, including homeopathy, has therefore attracted interest as a supportive approach rather than an alternative to evidence-based haematological treatment.



Pathophysiology of MDS**The pathological hallmarks include**

- Clonal stem cell mutations
- Ineffective haematopoiesis
- Bone marrow dysplasia
- Increased apoptosis
- Immune dysregulation
- Chronic inflammatory cytokine activation
- Progressive marrow failure

Common cytopenias include

- Anaemia
- Neutropenia
- Thrombocytopenia

Complications include

- Severe fatigue
- Opportunistic infections
- Haemorrhage
- Iron overload due to repeated transfusions
- Transformation into Acute Myeloid Leukaemia (AML)

Current Conventional Management**Standard treatment depends upon IPSS-R/IPSS-M risk stratification and includes**

- Observation
- Blood transfusions
- Platelet transfusions
- Iron chelation
- Erythropoiesis-stimulating agents
- Luspatercept
- Lenalidomide
- Azacitidine
- Decitabine
- Immunosuppressive therapy
- Allogeneic stem cell transplantation

Despite therapeutic advances, many patients remain transfusion dependent and symptomatic.

Rationale for Integrative Homeopathic Care

Homeopathy does not replace conventional haematology treatment

Instead, it has been explored for.

- Improvement of constitutional symptoms
- Reduction of fatigue
- Supportive management of chronic anaemia
- Better appetite and nutrition
- Psychological well-being

Frequently Reported Homeopathic Medicines

Homeopathic prescribing is individualized based on the totality of symptoms rather than diagnosis alone. The following remedies have been described in published literature concerning bone marrow disorders.

Medicine	Clinical Indications Reported
Calcarea phosphorica	Constitutional weakness, delayed marrow recovery, chronic anaemia
Ferrum phosphoricum	Early anaemia, fatigue, inflammatory states
Arsenicum album	Severe weakness, cachexia, anxiety, exhaustion
Phosphorus	Bleeding tendency, constitutional anaemia, marrow dysfunction

- Improvement in quality of life
- Possible reduction in transfusion frequency in selected observational reports

Current Clinical Literature**1. LM (50 Millesimal) Potencies**

Several clinical reviews have discussed the utilization of LM potencies in chronic haematological disorders.

Reported advantages include.

- Gentle dose response
- Frequent repetition
- Reduced aggravations
- Individualized prescription

LM potencies have been employed in long-term constitutional management of chronic disorders including marrow failure syndromes.

2. MDS with Ring Sideroblasts

Published case literature has documented patients diagnosed with.

- MDS with multilineage dysplasia
- Ring sideroblasts
- Chronic anaemia

Individualized homeopathic treatment was associated with

- Gradual improvement in haemoglobin
- Reduction in transfusion requirement
- Improved general health
- Better performance status

Although encouraging, such reports represent low-level clinical evidence and cannot establish causality.

3. Observational Experience in India

Observational work from integrative clinical settings in India has described supportive use of individualized homeopathy together with.

- Nutritional correction
- Vitamin supplementation were indicated
- Conventional haematology monitoring
- Lifestyle optimization

Reported outcomes include

- Improved constitutional health
- Better energy
- Stabilization of blood counts in selected patients
- Reduced symptom burden

These observations require confirmation through controlled clinical trials.

China officinalis	Debility after blood loss
Carbo vegetabilis	Collapse states, chronic exhaustion
Avena sativa Q	Supportive tonic for fatigue and nervous exhaustion
Lecithinum	Nutritional constitutional support reported in chronic anaemia

These remedies should not be interpreted as disease-specific treatments but rather as examples from published clinical reports.

Possible Biological Mechanisms

Emerging laboratory research has explored several hypotheses.

Potential mechanisms include.

Immunomodulation

Experimental studies suggest modulation of

- Cytokine balance
- Macrophage activity
- Immune regulation

Hematopoietic Support

Preclinical investigations have evaluated:

- Bone marrow progenitor differentiation
- Stem cell signalling
- Cellular proliferation

Oxidative Stress Reduction

Several experimental models report

- Reduced oxidative injury
- Improved antioxidant enzyme activity

Inflammatory Regulation

Possible influence on

- TNF- α
- IL-6
- NF- κ B pathways

These mechanisms remain exploratory and require further validation.

Quality of Life Outcomes

Across observational reports, improvements have been described in.

- Fatigue
- Appetite
- Sleep
- Emotional well-being
- Daily activities
- Functional performance
- Psychological resilience

Quality-of-life improvement may represent one of the most relevant endpoints for integrative supportive care.

Limitations of Current Evidence

Current literature has important limitations

- Mostly case reports
- Small sample sizes
- Lack of randomization
- Absence of placebo controls
- Publication bias

- Heterogeneous prescribing
- Variable follow-up
- Limited mechanistic evidence

Therefore, no definitive conclusions regarding efficacy can currently be drawn.

Future Research Priorities

Future studies should include

- Multicentre randomized controlled trials
- Standardized outcome measures
- Quality-of-life assessment
- Biomarker evaluation
- Cytokine profiling
- Bone marrow cellular studies
- Genomic correlation
- Long-term survival analysis
- Cost-effectiveness evaluation
- Integrative treatment protocols

Clinical Recommendations

For patients with MDS

- Continue treatment under a qualified haematologist.
- Homeopathy should be considered only as a complementary supportive approach, not a substitute for conventional therapy.
- Monitor complete blood counts, marrow status, and disease progression regularly.
- Individualized prescriptions should be made by qualified homeopathic physicians.
- Nutritional optimization and infection prevention remain essential components of care.

Conflict of Interest: None declared.

Funding: None.

Ethical Statement: This narrative review is based on published literature and does not involve new human participants or patient data.

CONCLUSION

Myelodysplastic Syndromes remain challenging disorders with significant morbidity and a substantial impact on patients' quality of life. Emerging clinical observations suggest that individualized homeopathy may have a role as supportive integrative care, particularly in improving constitutional symptoms and quality of life. Preliminary reports describing stabilization of blood counts and reduced transfusion requirements are promising but remain insufficient to establish efficacy.

Future high-quality clinical trials, translational research, and collaborative integrative haematology programs are

needed to determine whether homeopathy can contribute meaningfully to supportive care in MDS while maintaining adherence to evidence-based conventional management.

BIOGRAPHY

Dr. A. K. Dwivedi, BHMS (Gold Medallist), MD, MBA, Ph.D. has been a Registered Homeopaths for over 25 years. He is a Professor & HOD: Department of Physiology S.K.R.P. Gujarati Homoeopathic Medical College, Indore. He is a Member of Executive Council, Devi Ahilya Vishwavidyalaya Indore, MP, INDIA, he is also a Member, Ethical Committee (CCRH) Ministry of Ayush, Govt of India. Member, Scientific Advisory Committee (NEAH) Shilong Meghalaya, Ministry of Ayush, Govt. of India, Member Academic Board Madhya Pradesh Medical Science University, Jabalpur MP (India). DIRECTOR, & CEO Advanced Homeo Health Centre & Homeopathic Medical Research Pvt.Ltd. Indore, Madhya Pradesh, India, EDITOR, "SEHAT EVAM SURAT"(Hindi Monthly Medical Magazine).

REFERENCES

1. AK Dwivedi and Atharva Dwivedi, Homeopathy: An integrated approach for bone marrow disorders with blood & platelet transfusions, *International Journal of Homoeopathic Sciences*, 2025; 9(4): 977-979.
2. Dwivedi AK. Observational study: Aplastic anemia & homeopathic for adults. *Int J Homoeopathic Sci*, 2024; 8(2): 112-114.
3. Dwivedi AK. Aplastic anemia & homeopathic for children: Observational studies. *Int J Homoeopathic Sci*, 2024; 8(1): 307-310.
4. Dwivedi AK, Chaturvedi V, Dwivedi K. Homeopathy: A cure to fatal aplastic anemia. *Int J Sci Res*, 2022; 11(10). Print ISSN: 2277-8179.
5. Dwivedi AK. A case study: Aplastic anaemia. *Paripex: Indian J Res*, 2018; 7(6). Print ISSN: 2250-1991.
6. Dwivedi AK. Iron deficiency anemia & homeopathy medicines. *Indian J Appl Res*, 2019; 9(12).
7. Dwivedi AK. Anaemia in females: its causes, prevention, treatment & management with homeopathic remedies. *Paripex: Indian J Res*, 2019; 8(6). Print ISSN: 2250-1991.
8. Dwivedi AK. Aplastic anaemia & bone marrow diseases: its homeopathy treatment. *Traditional & Modern Medicine Conclave*, MGM Medical College, Indore; 2022 Jan.
9. Dwivedi AK. Symptomatic relief in sickle cell disease patients by homeopathy medicines.
10. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*, 2012; 120: 2454-2465.
11. DeZern AE, Binder G, Rizvi S, et al. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes. *Leuk Lymphoma*, 2017; 58: 2649-2656.
12. Khoury JD, Solary E, Abla O, et al. The 5th Edition of the WHO Classification of Haematolymphoid Tumours: Myeloid Neoplasms. *Leukemia*, 2022; 36: 1703-1719.
13. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms. *Blood*, 2022.
14. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Latest version.
15. Fenaux P, Platzbecker U, Mufti GJ. Current treatment strategies in MDS. *The Lancet*, 2020.
16. International Journal of Medical Research and Professional Studies. Reviews on LM (50 millesimal) potencies in chronic hematological disorders.
17. Saudi Journal of Medical and Pharmaceutical Sciences. Published case report on MDS with ring sideroblasts managed with individualized homeopathy.
18. Bellavite P, Marzotto M, Oliosio D, et al. Homeopathy and immunomodulation: experimental evidence. *Homeopathy*, 2019.
19. Witt CM, Lüdtke R, Willich SN. Homeopathic medical practice: systematic review. *BMC Complementary and Alternative Medicine*, 2005.
20. Mathie RT, et al. Randomized controlled trials of individualized homeopathy: systematic review and meta-analysis. *Systematic Reviews*, 2014.
21. World Health Organization. Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th Edition.
22. National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ®). Latest update.